This causes the cells to grow out of control. Like PIK3CA, HER2 is not an inherited gene mutation. Most breast cancer is HER2-negative. Research suggests about only 10% to 20% of cases are HER2 ...

Seth Wander, MD, PhD, discusses the significance of ESR1 mutations in patients with hormone receptor–positive, HER2-negative ...

In addition to genetic mutations, hormonal changes likely increase the risk of developing HR+/HER2- breast cancer. Several factors may increase the risk for HR+/HER2- breast cancer, including ...

Boehringer's zongertinib and Bayer's BAY 2927088 are in phase 3 testing for advanced non-small cell lung cancer (NSCLC) with activating HER2 mutations, and the WCLC congress gave an opportunity to ...

Alphamab Oncology (stock code: 9966.HK) and CSPC Pharmaceutical Group Co., Ltd. ("CSPC") (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has ...

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Assessment of HER2 is recommended in every newly diagnosed ... are dependent on the cancer type (i.e., kinase domain mutations in lung cancer, amplification in brain tumors and breast cancer ...

Findings from cohort 1, which included 75 patients with advanced NSCLC, showed a confirmed objective response rate of 71% among those with mutations in the HER2 tyrosine kinase domain; the disease ...

Zongertinib is being reviewed for the treatment of adults with unresectable or metastatic non-small cell lung cancer (NSCLC) whose tumours have HER2 mutations and who have received prior systemic ...

7 Baraibar I, et al. Novel drugs targeting EGFR and HER2 exon 20 mutations in metastatic NSCLC. Crit Rev Oncol Hematol. 2020;148:102906. 8 Li, B.T. et al. Trastuzumab Deruxtecan in HER2-Mutant Non ...

By Kolade Adeyemo / Jambar Contributor Breast cancer is one of the most prevalent cancers worldwide, affecting millions of ...

The FDA has granted priority review to the new drug application for zongertinib to treat adults with unresectable or metastatic, HER2-mutant NSCLC who have received prior systemic therapy.